Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.38 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized their commitment to pipeline development. There was no specific guidance provided for future performance.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its pipeline.
Crinetics Pharmaceuticals did not provide specific revenue figures or guidance, but the stock rose by 10.85% following the earnings report. This increase may reflect investor optimism about the company's future prospects and pipeline developments, despite the lack of detailed financial metrics. The market appears to be reacting positively to the overall direction of the company.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ADVANCE AUTO PTS INC
Nov 13, 2018